<span item_type="fundamental" item_id="b3906cc734cbca127d309eb35d0ea2eb" counter_id="ST/US/ICUCW" env="prod"></span><span item_type="announcement" item_id="582436326007570817" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 183 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.13.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.686 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenue for the three months ended September 30, 2025, was approximately $0.2 million, compared to $0.1 million for the same period in 2024, reflecting sales of the QUELIMMUNE pediatric SCD therapy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Cost of goods sold for the three months ended September 30, 2025, was $14 thousand, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>Research and development expenses decreased to $1.9 million from $2.3 million YoY, primarily due to a decline in consulting expenses and personnel costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>General and administrative expenses decreased to $1.9 million from $2.2 million YoY, due to lower franchise tax expense and a decline in legal and consulting fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>Net loss for the three months ended September 30, 2025, was approximately $3.5 million, or $0.13 per share, compared to a net loss of $4.5 million, or $1.10 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash at September 30, 2025, was $13.8 million, compared to $1.8 million at December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>Net cash used in operating activities for the nine months ended September 30, 2025, was - $9.5 million, compared to - $11.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>Net cash provided by financing activities for the nine months ended September 30, 2025, was $21.4 million, compared to $13.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Raised $12.4 million through equity offerings and exercise of warrants in the third quarter, strengthening the balance sheet.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>SeaStar Medical anticipates completing enrollment for the NEUTRALIZE-AKI pivotal clinical trial near the end of 2026, based on current enrollment rates and the addition of new clinical sites.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>The company expects strong QUELIMMUNE sales in the first half of the fourth quarter, with orders already exceeding those of the entire third quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li><li>SeaStar Medical aims to focus its cash resources on the development of its SCD therapy for adult patients with AKI requiring CRRT, targeting a market opportunity 50 times larger than the pediatric AKI market.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/ex_884838.htm"></span></li></ul>

SEASTAR MEDICAL HOLDING CORP C/WTS 28/10/2027 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 183 K